Skip to main content
SpringerLink
Log in

Procoagulant microparticles are increased in patients with Behçet’s disease but do not define a specific subset of clinical manifestations

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Microparticles (MP) are considered a key component in the haemostatic response. Beyond their in vitro procoagulant properties, a number of pieces of evidence points to procoagulant MP as efficient effectors in the haemostatic response and as pathogenic markers of thrombotic disorders and vascular damage. The aim of the present study was to analyze the procoagulant activity of MP and its correlation with clinical manifestations focusing on vascular involvement in patients with Behçet’s disease (BD). We analyzed 55 BD patients in inactive phase of the disease (26 men; mean age, 35 ± 15 years) of which 19 had previously suffered from thrombosis (deep venous thrombosis in 17 and ischemic stroke in 2), and 73 healthy controls matched for age and sex. Procoagulant MP were assessed by a functional assay. BD patients showed higher procoagulant MP values than controls (22.89 ± 15.74 nM versus 14.47 ± 7.34 nM; p < 0.0001). Conversely, we did not find differences in the levels of procoagulant MP according to the gender of patients (22.22 ± 16.23 nM for men versus 21.46 ± 16.47 for women; p = 0.846) or to previous and current treatments. Moreover, the plasmatic concentration of MP does not define any clinical phenotype and it was not related to the time of evolution of the disease. Although inactive BD patients had high values of procoagulant MP, they did not differentiate between BD patients with or without thrombosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1–11

    Article  CAS  PubMed  Google Scholar 

  2. Calamia KT, Schirmer M, Melikoglu M (2011) Major vessel involvement in Behçet’s disease: an update. Curr Opin Rheumatol 23:24–31

    Article  PubMed  Google Scholar 

  3. Hatemi G, Seyahi E, Fresko I, Hamuryudan V (2013) Behçet’s syndrome: a critical digest of the 2012–2013 literature. Clin Exp Rheumatol 31(3 Suppl 77):S108–S117

    Google Scholar 

  4. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D (2012) New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 11:687–698

    Article  CAS  PubMed  Google Scholar 

  5. Na S, Park M, Park S, Lee E (2013) Up-regulation of Th17 and related cytokines in Behçet’s disease corresponding to disease activity. Clin Exp Rheumatol 31(3 Suppl 77):S32–S40

    Google Scholar 

  6. Espinosa G, Font J, Tassies D et al (2002) Vascular involvement in Behcet’s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 112:37–43

    Article  CAS  PubMed  Google Scholar 

  7. Mendoza-Pinto C, García-Carrasco M, Jiménez-Hernández M et al (2010) Etiopathogenesis of Behçet’s disease. Autoimmun Rev 9:241–245

    Article  CAS  PubMed  Google Scholar 

  8. Reitsma PH, Versteeg HH, Middeldorp S (2012) Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol 32:563–568

    Article  CAS  PubMed  Google Scholar 

  9. Barteneva NS, Fasler-Kan E, Bernimoulin M et al (2013) Circulating microparticles: square the circle. BMC Cell Biol 14:23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Beyer C, Pisetsky DS (2010) The role of microparticles in the pathogenesis of rheumatic diseases. Nat Rev Rheumatol 6:21–29

    Article  CAS  PubMed  Google Scholar 

  11. Biro E, Nieuwland R, Tak PP et al (2007) Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals. Ann Rheum Dis 66:1085–1092

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ullal AJ, Reich CF 3rd, Clowse M et al (2011) Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus. J Autoimmun 36:173–180

    Article  CAS  PubMed  Google Scholar 

  13. (1990) International Study Group for Behcet’s disease. Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080

  14. Forbess C, Swearingen C, Yazici Y (2008) Behcet’s Syndrome Activity Score (BSAS): a new disease activity assessment tool, composed of patient-derived measures only, is strongly correlated with the Behcet’s Disease Current Activity Form (BDCAF). Arthritis Rheum 58(S9):S54

    Google Scholar 

  15. Muñoz-Saa I, Cambra A, Pallares L et al (2006) Allelic diversity and affinity variants of MICA are imbalanced in Spanish patients with Behçet’s disease. Scand J Immunol 64:77–82

    Article  PubMed  Google Scholar 

  16. Espinosa G, Arostegui JI, Plaza S, Rius J, Cervera R, Yague J, Font J (2005) Behçet’s disease and hereditary periodic fever syndromes. Casual association or causal relationship? Clin Exp Rheumatol 23(4 Suppl 38):S64–S66

    CAS  PubMed  Google Scholar 

  17. Saadoun D, Wechsler B, Desseaux K, Le Thi Huong D, Amoura Z, Resche-Rigon M, Cacoub P (2010) Mortality in Behcet’s disease. Arthritis Rheum 62:2806–2812

    Article  CAS  PubMed  Google Scholar 

  18. Enjeti AK, Lincz LF, Seldon M (2008) Microparticles in health and disease. Semin Thromb Hemost 34:683–691

    Article  PubMed  Google Scholar 

  19. Rectenwald JE, Myers DD Jr, Hawley AE et al (2005) d-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. a pilot study. Thromb Haemost 94:1312–1317

    CAS  PubMed  Google Scholar 

  20. Parker B, Al-Husain A, Pemberton P et al (2014) Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus. Ann Rheum Dis 73:1144–1150

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Sellam J, Proulle V, Jungel A et al (2009) Increased levels of circulating microparticles in primary Sjogren’s syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther 11:R156

    Article  PubMed  PubMed Central  Google Scholar 

  22. Vikerfors A, Mobarrez F, Bremme K et al (2012) Studies of microparticles in patients with the antiphospholipid syndrome (APS). Lupus 21:802–805

    Article  CAS  PubMed  Google Scholar 

  23. Iversen LV, Ostergaard O, Ullman S et al (2013) Circulating microparticles and plasma levels of soluble E- and P-selectins in patients with systemic sclerosis. Scand J Rheumatol 42:473–482

    Article  CAS  PubMed  Google Scholar 

  24. Baka Z, Senolt L, Vencovsky J, Mann H, Simon PS, Buzás E, Nagy G (2010) Increased serum concentrations of immune cell derived microparticles in polymyositis/dermatomyositis. Immunol Lett 128:124–130

    Article  CAS  PubMed  Google Scholar 

  25. Erdbruegger U, Grossheim M, Hertel B et al (2008) Diagnostic role of endothelial microparticles in vasculitis. Rheumatology 47:1820–1825

    Article  CAS  PubMed  Google Scholar 

  26. Yahata T, Suzuki C, Yoshioka A, Hamaoka A, Ikeda K (2014) Platelet activation dynamics evaluated using platelet-derived microparticles in Kawasaki disease. Circ J 78:188–193

    Article  CAS  PubMed  Google Scholar 

  27. Pisetsky DS, Ullal AJ, Gauley J, Ning TC (2012) Microparticles as mediators and biomarkers of rheumatic disease. Rheumatology 51:1737–1746

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Macey M, Hagi-Pavli E, Stewart J, Wallace GR, Stanford M, Shirlaw P, Fortune F (2011) Age, gender and disease-related platelet and neutrophil activation ex vivo in whole blood samples from patients with Behçet’s disease. Rheumatology 50:1849–1859

    Article  CAS  PubMed  Google Scholar 

  29. Mejia JC, Espinosa G, Tassies D, Reverter JC, Cervera R (2014) Endogenous thrombin potential in Behçet’s disease: relationship with thrombosis and anticoagulant therapy. Clin Exp Rheumatol 32(4 Suppl 84):S33–S39

    Google Scholar 

Download references

Disclosure

None

Author information

Author notes

    Authors and Affiliations

    1. Department of Autoimmune Diseases, Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain

      Juan Carlos Mejía, Ricard Cervera & Gerard Espinosa

    2. Department of Hemotherapy and Hemostasis, Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain

      Thaia Ortiz, Dolors Tàssies & Joan-Carles Reverter

    3. Department of Internal Medicine, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Catalonia, Spain

      Xavier Solanich & Antonio Vidaller

    Authors
    1. Juan Carlos Mejía
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Thaia Ortiz
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Dolors Tàssies
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Xavier Solanich
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Antonio Vidaller
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Ricard Cervera
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Joan-Carles Reverter
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Gerard Espinosa
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Gerard Espinosa.

    Additional information

    Juan Carlos Mejía and Thaia Ortiz contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Mejía, J.C., Ortiz, T., Tàssies, D. et al. Procoagulant microparticles are increased in patients with Behçet’s disease but do not define a specific subset of clinical manifestations. Clin Rheumatol 35, 695–699 (2016). https://doi.org/10.1007/s10067-015-2903-4

    Download citation

    • Received:

    • Revised:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s10067-015-2903-4

    Keywords

    Search

    Navigation